AnazaoHealth Corporation, Las Vegas, NV

Is AnazaoHealth Corporation registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names AnazaoHealth Corporation in Las Vegas, NV, first registered Sep 23, 2014 and most recently registered Dec 30, 2025.

Does AnazaoHealth Corporation hold a Nevada pharmacy license?

State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The California State Board of Pharmacy also lists nonresident license NSF 112 for Anazaohealth Corporation, Las Vegas, NV, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5234 for AnazaoHealth Corporation, Las Vegas, NV, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054016321 for ANAZAOHEALTH CORPORATION, LAS VEGAS, NV, status CHANGE OF OWNERSHIP and license 054019475 for ANAZAOHEALTH CORPORATION, LAS VEGAS, NV, status CLOSED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000330 for ANAZAO HEALTH CORPORATION, LAS VEGAS, NV, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001684 for AnazaoHealth Corporation, LAS VEGAS, NV, status Active, license AA-0000012 for AnazaoHealth Corporation, LAS VEGAS, NV, status Active, license A9-0000337 for AnazaoHealth Corporation, LAS VEGAS, NV, status Closed and license AA-0000006 for AnazaoHealth Corporation, LAS VEGAS, NV, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301011041 for AnazaoHealth Corporation, Las Vegas, NV, status Active, as of Nov 10, 2026.

Has AnazaoHealth Corporation had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Aug 18, 2021) for AnazaoHealth Corporation. State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The Colorado State Board of Pharmacy’s license dataset also lists 2 actions: “CLS Stipulation” dated Sep 29, 2016, case 2016-358 on nonresident license OSP 5234 and “CLS Stipulation” dated Sep 2, 2016, case 2015-5054 on nonresident license OSP 5234. The Virginia Department of Health Professions’ list of Board of Pharmacy case decisions from the last 90 days also lists “Monetary Penalty” dated Sep 15, 2026 on nonresident license 0236000023. The Maryland Board of Pharmacy’s posted orders against permit holders also lists an order whose title is not readable in the PDF text dated Jun 2, 2025 on nonresident permit D05656.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
AnazaoHealth Corporation; Anazaohealth Corporation
Location
Las Vegas, NV
Type as FDA labels it
503B
FDA 503B list
Listed as AnazaoHealth Corporation
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
1
Latest action on that page
Aug 8, 2025
FDA Data Dashboard inspections
5 inspections: 5 OAI; 7 published Form 483s
Form 483 text on this page
3 Form 483s, 16 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Anazaohealth Corporation, a 503B facility, with 6 dated actions.

Document
Aug 8, 2025Form 483483 issued 08/08/2025fda.gov
Sep 23, 2024Form 483483 Issued 09/23/2024fda.gov
May 2, 2023Regulatory meetingRegulatory Meeting Held 05/02/2023Not linked by FDA
Jul 29, 2022Form 483483 Issued 07/29/2022fda.gov
Aug 18, 2021Warning letterWarning Letter (08/18/2021)fda.gov
Sep 19, 2019Form 483483 Issued 09/19/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists AnazaoHealth Corporation, Las Vegas, NV (FEI number 3011152407), matched to this page by exact name, city and state. It lists 5 inspections: 5 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 8, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30111524071278379
Sep 23, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30111524071252328
Jul 29, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30111524071177831
Sep 19, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30111524071102395
Jan 30, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011152407913271

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 16 numbered observations in all, across 3 inspections ending Sep 19, 2019 to Aug 8, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 28, 2025 to Aug 8, 2025: 4 observations

Firm on the cover
AnazaoHealth Corporation, 7465 W Sunset Rd Ste 1200, Las Vegas, NV 89113-1944
FEI number
3011152407
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

A. Your firm's process validation for the pellet products intended for implantation does not assess pellet-to-pellet content uniformity. According to Process Validation for Testosterone 12.5 mg Pellet Q <Redacted B4> Document Number: VAL 097, dated 3/7/2018, Process Validation for Estradiol 6 mg Pellet Q <Redacted B4>, Document Number: VAL 101, dated 7/25/2018, and Analysis of Testosterone, Estradiol, or Naltrexre by ;PLC (cGMP Release Testing), Doc <Redacted B4> Dent Number AMl-1 319, at each stage of production -<Redacted B4> -your firm pooled 4H pellets of either Testosterone 12.5 mg or Estradiol 6 mg or testmg, which yielded passing results. However, no individual pellet was tested to assess uniformity, thereby failing to demonstrate content consistency across individual units. your firm produced approximately <Redacted B4> pellet batches per <Redacted B4>".

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A. During aseptic operations, the innermost sterile packaging layer of stoppers was routinely briefly exposed to the ISO 7 environment prior to transfer into the ISO 5 Laminar Airflow Hood (LAFH), without disinfection. For example, the camera footage shows that during the production of Ascorbic Acid30mL (PF-Non-Com), Lot # 1021502, Manufactured Date <Redacted B4>I, the <Redacted B4> outer layers of the stopper packaging were cut open by an operator in the ISO 7 buffer room, and the operator working at the ISO 5 LAFH then extended his gloved hands outside the hood to pull the inner layer directly from the ISO 7 area into the ISO 5 area, exposing the inner layer to the ISO 7 environment. Your firm produced approximately <Redacted B4> sterile batches of vial products per <Redacted B4>

B. Your firm has not conducted a hold time study to support the <Redacted B4> expiration period assigned to depyrogenized glassware and utensils used in the ISO 5 aseptic processing area. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Complaint records are deficient in that they do not include the findings of the investigation and follow-up.

Specifically,

Your firm's complaint investigation procedures are inadequate as investigations consistently fail to include retain sample testing when quality-related adverse events are reported. For example:

A. A provider reported multiple complaints potentially related to insertion site infections, including tenderness, pain, swelling, and/or inflammation after using Testosterone pellets at various dosages in 2025. Your firm's investigation concluded that no deficiencies were identified for these complaints; however, no retain sample testing was performed to evaluate potential sterility, bioburden, or other quality attributes that could contribute to infection reactions.

B A provider reported that three patients experienced burning sensations following administration of Ascorbic Acid (Preserved) 500mg/mL, Lot 740667 in 2025. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

Specifically,

A. Your firm does not test individual pellets for content uniformity during batch release of pellet product. Instead, your firm pools <Redacted B4> pellets from each batch for routine assay testing. For example, the batch record for Estradiol 10 mg pellet Q <Redacted B4>, Lot# 896276, manufactured on <Redacted B4> and the batch record of Testosterone 100 mg, Lot# 972948, manufactured on <Redacted B4> showed that the assay testing performed by a third-party laboratory yielded passing results in accordance with TEST AMI-1319, based on a <Redacted B4> of <Redacted B4> pellets. This practice does not evaluate the variability between individual dosage units and cannot ensure uniformity of strength as required by finished products specifications.

B. Your firm does not perform hardness testing for pellet drug products during batch release testing to ensure mechanical integrity and consistent quality of each lot produced. ...

Read the full 483 (PDF on fda.gov)

Inspection Mar 15, 2017 to Mar 4, 2020: 9 observations

Firm on the cover
AnazaoHealth Corporation, 7465 W. Sunset Road, Suite 1200, CODE
FEI number
3011152407
Establishment type on the cover
Outsourcing Facility La Vegas, NV 89113
FDA district office on the cover
Alameda, CA 94502
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically, during the redacted (b) (4) re-qualification of your r edacted (b) (4) , your firm failed to maintain y our sterilizing and depyroge nation redacted (b) (4) estab lish ed in yo ur protocol for redacted (b) (4) and depyrogenation. For example, the following criteria established in your protocols were not met during the redacted (b) (4) re-qualification:

....,....-;~.... Specifically, during the redacted (b) (4) re-qualification of your redacted (b) (4) , your firm failed to maintai n your sterilizing and depyrogenation redacted (b) (4) established in your protocol for redacted (b) (4) and depyrogenation. For example, the following criteria established in your protocols were not met during the redacted (b) (4) re-qualification:

Depyrogenation for 5mL glass vials (b) (4) -None ofthe'lb>! 4>

(15) (4) to ensure adequate depyrogenation. A. November 2016 redacted (b)(4) drug solution redacted (b)(4) depyrogenation for 5 mL glass vials redacted (b)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 2

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriat e laboratory testing.

Your firm lacks scientific justification for using red acte d (5)(4) Sterilization Validation method for steriliz ation of compounded pellet products which includes but are not limited to Testosterone, Testosterone/ Anastrozole, and

Estradiol products.

Your firm follows methods in ISO 11737 that consists of the following parts entitled re da cted (b)(4). Your firm lacks sufficient scientific justification to show this validation method is specific for your pharmaceutical pellet products.

Sterile pellet drug product batches produced for r (b ) (4 ) Jare not representative ofthe routine S terile pellet drug product batches products for redacted (b )(4) are not representativ e of the routine manufacturing batches. Your firm produces appr oximately redacted (b)(4); however, your firm’s routine manufacturing batches may produce up to redacted (b)(4).

Observation 3

Drug products failing to meet established specifications and quality control criteria are not rejected.

Specifically,

A. On 3/16/2016, we observed Pharmacy Technician redacted (b)(6) performing visual inspection of sterile injectab le drug product, MIC with Cyanocobalamin 25/50/50/1 mg per mL, 30mL vials, lot #031417-IKS-151641. Reda cted (b)(6) performed visual inspection for approximately 1.5 hours without taking any breaks. After these vi als passed visual inspection, we reviewed 9 vials from the lot and observed 2 vials appeared to have particle s or specs adhering to the inside of the glassware. This defect was confirmed by your firm’s Sterile Supe

rvisor redacted (b)(6) and redacted (b)(6) stated these vials should have been rejected per your firm’s visual inspection SOP.

In addition, we inspected Testosterone Cypionate 200mg/m L, lot #03 I 0 l7-2KS-151385, which had completed visual inspection. We observed particles in 4 vials out ofthe 2~ we, reviewed. These particles were .. confirmed by Sterile Supervisor'(b)(Sland Pharmacy Technicia.rC..<j\ccording to Sterile Supervisor<~>> <6>these vials should have been rejected per your firm's visual inspection SOP. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.

Specifically, our review of your firm's visual inspection redacted (b) (4) reveale d the redacted (b)(4) does n ot reflect actual vials encountered during the visual inspection process. Fo r example , the redacted (b)(4) does not in clude a representative vial with a pink colored solution in an amber colored vial similar to what is observed in MIC with Cyanocobalamin injectable products and Methylcobalamin injectable products. We also observed particle s in test vials #2, 17, 23, and 52 which were labeled as controls (without particles or defects). We revi

ewed the visual inspection redacted (b)(4) results and found while some technicians were able to identify the same particles, others did not, indicating the technicians are not properly trained and fully qualified t o pe rform visual ins pection . The red acted ( b) (4) also includes redacted (b)(4) such as (b)(4).

Observation 5

Written records are not always made of investigation s into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.

Specifically, we reviewed the alarm settings and temperature recording for redacted (b)(4) incubators and reda

cted (b) (4 ) on 3/22/2017 and observed the following deficiencies:

A. Your firm has not set high and low alarms for the temperature of your firm's Incubator redac ted (b)(4). The incuba tor is used to incubate environmental monitoring sam ples fro m redacted (b) (4).We reviewed the temperature

recordings for the previous year and observed on numerous occasions the incubator dropped below the redacte d (b)(4) lower limit including on 11/15/2016 when the temperature was out of range for more than 10 hours duri ng the incubation of environmental monitoring samples. Your firm has not investigated these events to ens ure the samples in the incubator are not affected.

B. Your firm's alarm settings for redacted (b)(4) are not configured to notify you when the temperature drops redacted (b)(4). The redacted (b)(4) is used to store environmental monitoring samples that are required to be incubated at redacted (b)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 6

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

On redacted (b)(4), we observed media fill ba tch reda cted (b)(4) on a metal shelf in the hallway outside ante r

oom r edac ted (b)(4). There is no temperature probe physically close to this area and no d ocumented temperature monitoring of this hallway. Your firm does not have data to determine whether or not the media fill batch was incubated at the appropriate redacted (b)(4) temperature requirement for redacted (b)(4).

Observation 7

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm does not review the pressure differential data to ensure there were no unacceptable losses of pressure obtained during manufacturing operations in your clean rooms. Your firm only reviews alarms however your r edacted (b)(4) system is set to only redacted (b)(4). Your firm does not have any justification for choosing redacted (b)(4) as your criteria for redacted (b)(4). Specifically, your firm does not review the pressure differential data to ensure there were no unacceptable losses of pressure obtained during manufacturing operations in your clean rooms. Your firm only reviews alarms however your redacted (b)(4) system is set to only redacted (b)(4). Your firm does not have any justification for choosing redacted (b)(4) as your criteria for redacted (b)(4).

Specifically, your firm does not review the pressure differential data to ensure there were no unacceptable losses of pressure obtained during manufacturing operations in your clean rooms. Your firm only reviews alarms however your redacted (b)(4) system is set to only redacted (b)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 8

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for th e duties they perform.

Specifically, your firm's technicians wear sterile goggles for redacted (b)(4) prior to discarding the goggles. These goggles are sanitized with redacted (b)(4). However, your firm failed to properly validate the cleanroom goggle sanitization process. Cleanroom Goggles Sterilization Validation VAL 033 is inadequate in that samples collected were not transported to the testing laboratory within the required time frame. Redacted (b)(4). Validation samples from weeks 2 and 3 did not reach the testing laboratory within the required time frame. However, your firm accepted the results and established your cleanroom goggle sanitization time periods based on these invalid test results. Specifi ca lly, your firm's technicians wear sterile goggles for redacted (b)(4) prior to discarding the goggles. These goggles are sanitized with redacted (b)(4). However, your firm failed to properly validate the cleanroom goggle sanitization process. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that is registered under section 510 as required by section 503B(a)(2)(C).

Specifically,

On 03/21/2017, the following bulk drug substance manufacturer was identified as not being registered with the FDA:

redacted (b)(4) I 1

The inositol raw ingredient is used in the production of the following finished products:

• Methionine/Inositol/Choline (MIC) 25/50/50 mg/ml 30m! • MIC with Cyanocobalamin 25/50/50/1 mg/ml30 ml • MIC with Cyanocobalamin 25/50/50/1 mglml4 ml

Inspection Sep 9, 2019 to Sep 19, 2019: 3 observations

Firm on the cover
AnazaoHealth Corporation, 7465 W Sunset Rd Ste 1200, Las Vegas, NV 89113-194 4
FEI number
3011152407
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A) Following the cleaning of classified laminar flow hoods/biosafety cabinets and clean rooms, your firm does not require a visual inspection to check that the cleaning has been completed and that it was effective. With any type of cleaning there needs to be some type of verification process in place.

During inspection walk-through on September 91 \ I noted the following:

{I>) (4I

tb) (4) 1) An accumulation of cleaning residue from present and past cleaning . was found in LFH <Redacted B4> Cleanroom The residue was located in the back, right hand comer of the LFH <Redacted B4> (or( <Redacted B4> In addition, small cracks/fractures (less than the size of a Washington quarter) were observed in the <Redacted B4> side • paneling • <Redacted B4> LFHs # <Redacted B4> and # <Redacted B4> .

2 ) A small feel of plastic (1/2-inch x 1/8 inch) was observed stuck in the <Redacted B4> front grill of BSC # <Redacted B4> Cleanroom <Redacted B4> ...

Read the full 483 (PDF on fda.gov)

Observation 2

~~;( The flow of components, drug product containers, closures and in-process materials -through the building is not designed to prevent contamination.

~¥' Specifically,

<Redacted B4> your sterile compounding clean rooms <Redacted B4> have <Redacted B4> the ISO 7 buffer rooms to unclassified work spaces. Equipment and components are <Redacted B4> prior to and during sterile production.

These <Redacted B4> are not designed with interlocking mechanisms to prevent cross-contamination of the adjoining spaces <Redacted B4> door at a time can open.

Observation 3

Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that is registered under section 510 of the FDCA as required by section 503(a)(2)(C).

Specifically,

Although you are receiving bulk drug substances from FDA-registered suppliers, you have neither verified these components are manufactured in an FDA-registered establishment nor established a supplier quality agreement that ensures the component's pedigree. An example of suppliers and components with insufficient quality agreements, include: <Redacted B4> <Redacted B4>

- (b) (4)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NSF 112Nonresident Outsourcing FacilityAnazaohealth CorporationLas Vegas, NVActive

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5234OSPAnazaoHealth CorporationLas Vegas, NVExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054016321LICENSED PHARMACYANAZAOHEALTH CORPORATIONLAS VEGAS, NVCHANGE OF OWNERSHIP
054019475LICENSED PHARMACYANAZAOHEALTH CORPORATIONLAS VEGAS, NVCLOSED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0000330NONRESIDENT PHARMACYANAZAO HEALTH CORPORATIONLAS VEGAS, NVACTIVE (CURRENT)

Virginia Board of Pharmacy, board actions read Nov 15, 2026 (Virginia).

Maryland Board of Pharmacy, board actions read Nov 15, 2026 (Maryland).

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001684Non Resident PharmacyAnazaoHealth CorporationLAS VEGAS, NVActive
AA-0000012Outsourcing Facility-PharmacyAnazaoHealth CorporationLAS VEGAS, NVActive
A9-0000337Non Resident PharmacyAnazaoHealth CorporationLAS VEGAS, NVClosed
AA-0000006Outsourcing Facility-PharmacyAnazaoHealth CorporationLAS VEGAS, NVClosed

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301011041PharmacyAnazaoHealth CorporationLas Vegas, NVActive

FDA’s 503B list

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming tirzepatide under the labeler name “AnazaoHealth Corporation”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
72682-1205Tirzepatide 5mg/mL 2mLTirzepatide 5mg/mL Injection 2mLINJECTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs
72682-1220Tirzepatide 20mg/mL 2mLTirzepatide 20mg/mL 2mLINJECTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.